Description_x000D_ Packaging_x000D_ 5, 25 mg in glass bottle_x000D_ Biochem/physiol Actions_x000D_ CBP BRD (CREB binding protein bromodomain) inhibition serves as an effective therapeutic target for Parkinson’s disease. The inhibition is followed by negative regulation of a number of macrophage inflammatory genes. It also downregulates G-protein signaling 4 mRNA._x000D_ ISOX-INACT is an inactive control probe for the highly-selective inhibitor of the bromodomain of CREB binding protein (CBP BRD) PF-CBP1._x000D_ Other Notes_x000D_ This compound was developed by Pfizer for Gene Regulation research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer._x000D_ Legal Information_x000D_ Sold for research purposes under agreement from Pfizer Inc._x000D_ Pfizer is a registered trademark of Pfizer, Inc.